Monoclonal Antibodies against SARS-CoV-2 Infection: Results from a Real-Life Study before the Omicron Surge

Despite the lightning-fast advances in the management of SARS-CoV after 2 years of pandemic, COVID-19 continues to pose a challenge for fragile patients, who could benefit from early administration of monoclonal antibodies (mAbs) to reduce the risk of severe disease progression. We conducted a prosp...

Descripción completa

Detalles Bibliográficos
Autores principales: Scotto, Riccardo, Buonomo, Antonio Riccardo, Zumbo, Giulia, Di Fusco, Antonio, Esposito, Nunzia, Di Filippo, Isabella, Nobile, Mariano, Pinchera, Biagio, Schiano Moriello, Nicola, Villari, Riccardo, Gentile, Ivan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693092/
https://www.ncbi.nlm.nih.gov/pubmed/36366403
http://dx.doi.org/10.3390/vaccines10111895

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693092/
https://www.ncbi.nlm.nih.gov/pubmed/36366403
http://dx.doi.org/10.3390/vaccines10111895

Ejemplares similares